BofA update shows where active managers are putting money
Joseph Burnett, CEO and President of ClearPoint Neuro, Inc. (NASDAQ:CLPT), recently sold 21,247 shares of the company’s common stock. The shares were sold at an average price of $13.29, resulting in a total transaction value of approximately $282,372. The transaction comes as CLPT shows impressive momentum, with the stock delivering a 127% return over the past year according to InvestingPro data. Following this transaction, Burnett holds 243,522 shares indirectly through the Joseph M. Burnett Trust. The sale was part of a net share settlement related to a restricted stock unit that vested earlier this year. With a market capitalization of $363 million and analyst price targets ranging from $28-30, InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report that provides detailed analysis of CLPT’s financial health and growth prospects.
In other recent news, ClearPoint Neuro Inc. reported first-quarter 2025 revenue of $8.5 million, exceeding analyst forecasts by 3.16%. This figure marks an 11% increase compared to the same period last year, driven largely by a 70% growth in the Neurosurgery Navigation segment. However, the company noted a significant 63% decrease in Capital Equipment and Software (ETR:SOWGn) revenue, highlighting areas that may require attention. ClearPoint Neuro’s operational cash burn increased by $2.3 million, raising potential concerns about financial resource management. The company has also secured new funding from Overland Capital, providing flexibility for future strategic initiatives. ClearPoint Neuro plans to activate 15 to 20 new sites this year and is pursuing GLP certification, which could enhance its commercial capabilities. In terms of analyst activity, Lake Street Capital Markets and B. Riley Securities have shown interest in the company’s strategic direction and recent financing efforts. These developments reflect ClearPoint Neuro’s ongoing efforts to expand its market presence and innovate within the neurosurgery field.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.